Laura Castillo-Saavedra and Nigel Gebodh from Harvard Medical School — in collaboration with colleagues from the U.S., Brazil, and Israel — argue that the lack of clinical efficacy reported in many studies is mainly associated with a lack of consistency in clinical trial design and stimulation parameters.Optimization and standardization of the treatment framework might lead to large improvements in the clinical efficacy of transcranial direct current stimulation. The study was performed as a Phase 2 open-label clinical trial encompassing only FM patients. The patients were asked to continue treatment until they experienced a clinically meaningful reduction in pain. Maximum treatment time was six weeks. The study, titled "Clinically Effective Treatment of Fibromyalgia Pain With High-Definition Transcranial Direct Current Stimulation: Phase II Open-Label Dose Optimization," was published in the Journal
Researchers have evaluated optimal stimulation parameters and criteria for the use of transcranial direct current stimulation in patients with fibromyalgia (FM) pain. Positive effects of transcranial direct current stimulation for FM pain have been reported in several studies, but results tend to be inconsistent. Since studies often produce limited and marginal clinical results, the stimulation is thought to show a lack of coupling between neurophysiologic responses in the areas stimulated and improvements in signs and symptoms in FM patients.